Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Laetsch, Theodore W
[Clear All Filters]
2018
Kansagra AJ
,
Frey NV
,
Bar M
,
Laetsch TW
,
Carpenter PA
,
Savani BN
,
Heslop HE
,
Bollard CM
,
Komanduri KV
,
Gastineau DA
, et al.
Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl
. Biol Blood Marrow Transplant. 2018.
PubMed
Google Scholar
2019
Laetsch TW
,
Myers GDouglas
,
Baruchel A
,
Dietz AC
,
Pulsipher MA
,
Bittencourt H
,
Buechner J
,
de Moerloose B
,
Davis KL
,
Nemecek E
, et al.
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Lancet Oncol. 2019.
PubMed
Google Scholar
2022
Laetsch TW
,
Maude SL
,
Rives S
,
Hiramatsu H
,
Bittencourt H
,
Bader P
,
Baruchel A
,
Boyer M
,
de Moerloose B
,
Qayed M
, et al.
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
J Clin Oncol. 2022:JCO2200642.
PubMed
Google Scholar
2023
Eylon M
,
Prabhu S
,
John S
,
King MJM
,
Bhatt D
,
Curran KJ
,
Erickson C
,
Karras NA
,
Phillips CL
,
Satwani P
, et al.
Mediport use as an acceptable standard for CAR T cell infusion.
Front Immunol. 2023;14:1239132.
PubMed
Google Scholar
McNerney KO
,
Moskop A
,
Winestone LE
,
Baggott C
,
Talano J-A
,
Schiff D
,
Rossoff J
,
Modi A
,
Verneris MR
,
Laetsch TW
, et al.
Practice preferences for consolidative HSCT following tisagenlecleucel in children and young adults with B-ALL.
Transplant Cell Ther. 2023.
PubMed
Google Scholar
Barsan V
,
Li Y
,
Prabhu S
,
Baggott C
,
Nguyen K
,
Pacenta H
,
Phillips CL
,
Rossoff J
,
Stefanski H
,
Talano J-A
, et al.
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns.
EClinicalMedicine. 2023;65:102268.
PubMed
Google Scholar